Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial - Garassino, Marina; Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta; Speranza, Giovanna; Domine, Manuel; Hochmair, Maximilian J.; Powell, Steven; Cheng, Susanna Yee-Shan; Bischoff, Helge; Peled, Nir; Reck, Martin; et al. (The lancet. Oncology, 2020)
Gesehen am 30.10.2020